Bharat Parenterals Ltd (BPLPHARMA) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Bharat Parenterals Ltd on NSE and BSE, with an AI summary of each filing.
Transcript of Earnings Conference Call of Q2FY27.
Transcript · 02 Nov 2026, 9:25 pm
Audio Recording of Q2FY27 Earnings Conference Call.
Audio / Video · 30 Oct 2026, 11:52 pm
Bharat Parenterals Releases Audio Recording of Q2FY27 Earnings Conference Call Bharat Parenterals Limited has hosted the audio recording of its Q2FY27 earnings conference call on its official website pursuant to SEBI LODR Regulations. The call, conducted on 30th Oct'26 at 4:00 PM IST, discussed the company's operational and financial performance for the quarter and half-year ended 30th Sep'26. Investors can access the recording via the company's dedicated investor relations portal.
Investor Presentation for the Quarter and Half Year ended on September 30, 2026.
Investor Presentation · 29 Oct 2026, 10:44 pm
Bharat Parenterals Q2 FY27 Consolidated Results And Growth Strategy Bharat Parenterals reported consolidated Q2 FY27 revenue of ₹136.3 Cr (+110.9% YoY, +45.4% QoQ), with operating EBITDA surging to ₹23.6 Cr (17.3% margin) and PAT reaching ₹11.8 Cr (₹9.4 Cr to owners), driven by subsidiary Innoxel's turnaround to ₹5.4 Cr PAT and ₹44.5 Cr revenue (+253.1% YoY). BPL Standalone generated ₹78.6 Cr revenue (+88.4% YoY) with ₹117.83 Cr in orders as of 30th Sep'26. Additionally, the company approved a ₹139 Cr preferential issue to fund expansion, including Varenyam Bio’s revised ₹300 Cr biologics CDMO facility.
Un-Audited Standalone and Consolidated Financial Results For the Quarter and Half Year Ended On September 30, 2026.
Financial Result · 29 Oct 2026, 10:35 pm
Outcome of the Meeting of the Board of Director of Bharat Parenterals Limited held on October 29, 2026
Outcome · 29 Oct 2026, 10:25 pm
Bharat Parenterals Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Lakh) ■ Revenue: 13,628 (+110.9% YoY | +45.4% QoQ) ■ EBITDA: 2,358 (+2762.5% YoY | +176.3% QoQ) ■ EBITDA Margin (%): 17.3 (+1603 bps YoY | +820 bps QoQ) ■ PAT: 942 (Loss to Profit YoY | +834.4% QoQ) ■ EPS (INR): 17.2 (Loss to Profit YoY | Loss to Profit QoQ)
Approval of Preferential Issue by Shareholders of the Company through EGM Held on October 23, 2026.
Others (Uncategorized) · 25 Oct 2026, 8:07 pm
Bharat Parenterals Shareholders Approve Preferential Issue and Investment Limits at EGM Bharat Parenterals Limited announced that shareholders approved all special resolutions at the EGM held on 23rd Oct'26 with 100% majority of polled votes. The approved items include the preferential issuance of equity shares and authorization for investments, loans, guarantees, and securities exceeding limits under Section 186(2) of the Companies Act, 2013. A total of 4,879,194 votes were polled (78.71% of outstanding shares), all cast in favor via remote e-voting. A revised filing was submitted on 25th Oct'26 to correct shareholder categorization without altering vote tallies.
Revised Voting Result
Extra Ordinary General Meeting · 25 Oct 2026, 8:04 pm
Bharat Parenterals Shareholders Unanimously Approve Preferential Issue and Investment Limits Bharat Parenterals Limited submitted revised voting results for its EGM held on 23rd Oct'26 to rectify shareholder categorisation errors between Public–Institutions and Public–Non-Institutions, with no impact on vote counts or outcomes. Shareholders passed both special resolutions with 100% approval across 4,879,194 votes polled (78.71% turnout). Key approvals comprise the issuance of equity shares on a preferential basis and authorization to make investments, extend loans, provide guarantees, and offer security exceeding limits under Section 186(2) of the Companies Act, 2013.
Approval of Preferential Issue by shareholders of the company through EGM held on October 23, 2026.
Others (Uncategorized) · 24 Oct 2026, 11:13 pm
Bharat Parenterals Shareholders Approve Preferential Issue and Enhanced Investment Limits Bharat Parenterals Limited announced that shareholders approved two special resolutions with 100% majority at its EGM held on 23rd Oct'26. The approved measures include the issuance of equity shares on a preferential basis and authorization to make investments, extend loans, give guarantees, and provide securities exceeding limits under Section 186(2) of the Companies Act, 2013. A total of 4,879,194 votes were cast via remote e-voting across 69 members, representing 70.80% of total voting rights, with zero dissenting or invalid votes recorded.
Voting Results and Scrutinizer Report for the EGM held on October 23, 2026.
Extra Ordinary General Meeting · 24 Oct 2026, 11:09 pm
Bharat Parenterals Shareholders Approve Preferential Issue and Enhanced Investment Limits Bharat Parenterals Limited announced that shareholders approved two special resolutions at its Extraordinary General Meeting held on 23rd Oct'26. The passed resolutions include the issuance of equity shares on a preferential basis and authorization to exceed investment, loan, guarantee, and security limits under Section 186(2) of the Companies Act, 2013. Both proposals were passed unanimously via remote e-voting, with 100% of the 4,879,194 polled votes cast in favor, representing 70.80% of total outstanding shares across 69 voting members.
Intimation of Q2FY27 Earnings Conference Call.
Intimation · 30 Oct 2026, 4:00 pm
Bharat Parenterals Schedules Q2 & H1FY27 Earnings Conference Call Bharat Parenterals Limited will host its Q2 and H1FY27 earnings conference call on Friday, 30th Oct'26 at 4:00 PM IST to discuss operational and financial performance for the period ended 30th Sep'26. Organized by PhillipCapital (India) Private Limited, the call will feature Mr. Bhahim Desai, Director (Strategy & Investor Relations). Primary access numbers are +91 22 6280 1143 and +91 22 7115 8044, alongside international toll-free options for the USA, UK, Singapore, and Hong Kong.
Bharat Parenterals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/10/2026 ,inter alia, to consider and approve Unaudited standalone and ....
Intimation · 29 Oct 2026, 5:30 am
Bharat Parenterals Schedules Board Meeting for Q2 FY27 Financial Results Bharat Parenterals Limited has scheduled a Board of Directors meeting on 29th Oct'26 to consider, approve, and take on record the unaudited standalone and consolidated financial results for the quarter and half-year ended 30th Sep'26. In compliance with insider trading regulations, the trading window for dealing in company securities by designated persons and their immediate relatives has been closed effective 1st Oct'26 and will remain shut until 48 hours post the declaration of the financial results.
Proceedings of the EGM held on Friday, October 23, 2026, through Video conferencing.
Extra Ordinary General Meeting · 23 Oct 2026, 8:54 pm
Bharat Parenterals Concludes EGM for Preferential Issue and Investment Limits Approval Bharat Parenterals Limited conducted its Extraordinary General Meeting on 23rd Oct'26 via video conferencing to seek shareholder approval for two special resolutions. The key proposals presented included the issuance of equity shares on a preferential basis for fundraising and investment in subsidiaries, alongside approval for making investments, extending loans, and providing guarantees in excess of the limits specified under Section 186(2) of the Companies Act, 2013. Voting results will be declared and published on the company's website within two working days.
Press Release on Commencement of Commercial Supply to the U.S by Innoxel Lifesciences Private Limited, Material Subsidiary Company of Bharat Parenterals Limited.
Press Release · 21 Oct 2026, 6:59 pm
Bharat Parenterals Subsidiary Innoxel Commences Commercial Supply to the US Market Bharat Parenterals’ 55.9% subsidiary, Innoxel Lifesciences, commenced commercial supply to the US with its first CMO product launched on 20th Oct'26. Manufactured at its Vadodara facility—holding US FDA EIR (Jul'25) and EU-GMP certification (Mar'26)—this marks the first of two planned FY27 CMO launches. Commercial supply introduces recurring revenue alongside licensing income, which drove all ₹72.4 crore of FY26 revenue (₹17.1 crore upfront, ₹55.3 crore milestone-linked). Innoxel signed 23 deals in FY26 (48 total since inception) and actively partners with 19 entities across the US, EU, and India.
We hereby submit the corrigendum to the Extra-Ordinary General Meeting to be held on October 23, 2026.
Extra Ordinary General Meeting · 13 Oct 2026, 8:55 pm
Bharat Parenterals Appoints Crisil as Monitoring Agency for Preferential Issue Bharat Parenterals Limited has issued a corrigendum to the notice for its Extraordinary General Meeting scheduled for 23rd Oct'26. Following BSE directives during the in-principle approval process for its proposed preferential issue of equity shares, the company disclosed that the issue size exceeds INR 100 crore. Consequently, under SEBI ICDR Regulations, Bharat Parenterals has appointed Crisil Ratings Limited as the monitoring agency to oversee the utilization of the preferential issue proceeds. All other details and resolutions in the EGM notice remain unchanged.
Notice of Extra -Ordinary General Meeting of the Company to be held on Friday, October 23, 2026.
Extra Ordinary General Meeting · 01 Oct 2026, 11:09 pm
Bharat Parenterals Proposes ₹139 Crore Preferential Issue and Enhanced Investment Limits Bharat Parenterals scheduled an EGM for 23rd Oct'26 to approve raising up to ₹139.00 crore via a preferential issue of 9,12,759 equity shares at ₹1,522.85 per share to non-promoter institutional and individual investors, including WhiteOak Capital entities. Proceeds will primarily fund investments in subsidiaries (up to ₹135.00 crore) and general corporate purposes. The issue will dilute promoter holding from 67.20% to 59.35%. Additionally, the company seeks shareholder approval to enhance its investment, loan, guarantee, and security limits under Section 186 up to ₹140.00 crore.
Outcome of the board meeting for the board approves the Preferential Allotment
Outcome · 29 Sept 2026, 9:52 pm
Bharat Parenterals Approves ₹139 Crore Preferential Issue to Institutional Investors Bharat Parenterals' board approved a preferential allotment of up to 9,12,759 equity shares (face value ₹10) at ₹1,522.85 per share, raising ₹138.99 crore from 15 non-promoter investors, including WhiteOak Capital entities and Aurum Rising India Fund. Post-allotment, these investors will hold a combined 12.11% stake. The board also approved investing in or providing loans to subsidiaries for project development. An Extraordinary General Meeting is scheduled for 23rd Oct'26 to obtain shareholder approval for the proposed issue.
Bharat Parenterals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/09/2026 ,inter alia, to consider and approve Intimation of Board Meeting ....
Intimation · 24 Sept 2026, 7:58 pm
Bharat Parenterals Board to Consider Preferential Issue on 29th Sep'26 Bharat Parenterals Limited's Board of Directors is scheduled to meet on 29th Sep'26 to evaluate and approve a proposal for issuing equity shares or other eligible securities via a preferential issue, alongside incidental business matters. Consequently, the trading window for dealing in company securities is closed for designated persons and their immediate relatives with immediate effect from 24th Sep'26, reopening 48 hours after the conclusion of the board meeting.
Voting Results along with the scrutinizer report for the 33rd AGM held on Saturday, September 19, 2026.
Annual General Meeting · 19 Sept 2026, 10:27 pm
Intimation of Proceedings of the 33rd Annual General Meeting of the Company held on September 19, 2026.
Annual General Meeting · 19 Sept 2026, 7:21 pm
Please find the enclosed copy of the letter dispatched by the company to the shareholders (whose email id not registered) for providing details to access the Annual Report for FY 2025-26.
Annual Report · 27 Aug 2026, 10:47 pm
Intimation of Record Date for the purpose of Payment of Dividend for the FY 2025-26.
Dividend · 27 Aug 2026, 10:40 pm
Bharat Parenterals Sets Record Date for FY26 Dividend Bharat Parenterals (BSE: 541096) has fixed Saturday, Sep 12, '26, as the record date for determining shareholder entitlement to the dividend for FY 2025-26. The dividend payment is subject to approval by members at the upcoming Annual General Meeting (AGM) scheduled for Sep 19, '26. Shareholders recorded as beneficial owners on the record date will be eligible for the dividend.
Annual Report for the Financial Year 2025-26
Others (Uncategorized) · 27 Aug 2026, 10:35 pm
Notice of 33rd Annual General Meeting of the Company.
Annual General Meeting · 27 Aug 2026, 9:11 pm
Intimation regarding permission to trade and Admission of Equity Shares to dealing on the National Stock Exchange of India Limited.
Others (Uncategorized) · 20 Aug 2026, 6:08 pm
Bharat Parenterals (BPLPHARMA) Equity Shares Admitted to Trading on NSE Bharat Parenterals announced its equity shares are now permitted to trade on the National Stock Exchange (NSE) effective 17 Aug’26, in addition to its existing BSE listing. As per NSE circular dated 14 Aug’26, the stock (Symbol: BPLPHARMA) will trade under the "Permitted to Trade" category on the Capital Market Segment. This move is expected to enhance liquidity and accessibility for investors. The scrip's face value is ₹10 with a total of 6,891,963 securities admitted for trading.
Press release on Update on Expansion and Enhancement of the facility of Varenyam Biolifesciences Pvt Ltd, a Wholly Owned Subsidiary Company of Bharat Parenterals Limited
Press Release · 11 Aug 2026, 9:09 pm
Bharat Parenterals Doubles Capex for High-Value Biologics CDMO Facility Bharat Parenterals' subsidiary, Varenyam Biolifesciences, is upgrading its Savli facility to add biologics/biosimilar CDMO capabilities alongside its existing oncology focus. Approved on 11 Aug'26, the revised Phase 1 capex is doubled to ₹300 crore from ₹150 crore. This strategic shift targets higher-value regulated markets, including the US and EU, moving beyond its original Rest-of-World scope. The company will pursue USFDA and EU-GMP approvals, with project completion expected in Q2 2028, aiming to capture growth in the biologics manufacturing supply chain.